Floatz logo

AZD 8186

Advanced Malignant Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

124 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2B
Vinorelbine
OHSU Knight Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

AZD 8186 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →